Skip to main content

Advertisement

Table 5 Univariate and multivariate analyses of clinical variables on overall survival

From: Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis

  Univariate
HR (95% CI)
P Multivariate
HR (95% CI)
P
Age (≥60/< 60) 1.17 (0.58–2.36) 0.667   
Gender (Female/Male) 0.61 (0.29–1.23) 0.158   
Smoking status (Smoking/Never) 1.61 (0.74–3.51) 0.225   
KPS (≥80/< 80) 0.39 (0.19–0.84) 0.012 0.43 (0.19–0.94) 0.034
EGFR mutation (exon 19 deletion/exon 21 L858R) 0.79 (0.39–1.58) 0.495   
Co-existing BMs (yes/no) 0.57 (0.22–1.51) 0.25   
Intracranial symptoms (yes/no) 1.31 (0.54–3.17) 0.554   
LM at the time of NSCLC diagnosis (yes/no) 0.35 (0.11–1.14) 0.066   
Treatment for LM
 WBRT (yes/no) 0.45 (0.23–0.91) 0.022 0.49 (0.24–1.01) 0.54
 EGFR-TKIs (yes/no) 0.31 (0.15–0.67) 0.002 0.26 (0.11–0.58) 0.001
 WBRT+EGFR-TKIs/EGFR-TKIs alone 0.68 (0.29–1.61) 0.381   
  1. LM Leptomeningeal metastasis, KPS Karnofsky performance status, NSCLC Non-small-cell lung cancer, EGFR Epidermal growth factor receptor, TKI Tyrosine kinase inhibitor, WBRT Whole brain radiotherapy, ChT Chemotherapy, BMs Brain metastases